# File Descriptions

All datasets are formatted to contain antibody variable domain sequence (heavy chain + light chain or heavy chain only), and one or more fitness metric.

| filename                                   | size | assay/units                        | description                       | publication                                                                                  | year |
|--------------------------------------------|------|----------------------------------|----------------------------------|----------------------------------------------------------------------------------------------|------|
| jain2017biophysical_BVPELISA.csv            | 137  | BVP ELISA                        | clinical stage therapeutic, Fv   | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_CICRT.csv                | 137  | CIC Retention Time (Min)          | clinical stage therapeutic, Fv   | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_ELISA.csv                 | 137  | ELISA                           | clinical stage therapeutic, Fv   | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_PSR.csv                    | 137  | Poly-Specficity Reagent (PSR) SMP Score (0-1) | clinical stage therapeutic, Fv   | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_SMACRT.csv               | 137  | SMAC Retention Time (Min)a        | clinical stage therapeutic, Fv   | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2023identifying_DNP.csv                   | 112  | DNP                            | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_FA2.csv                    | 113  | FA.2                           | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_FVC32.csv                  | 115  | Fe.C3.2                        | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_FvFVIII2.csv               | 115  | Fe.FVIII.2                     | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_FvLysM2.csv                | 115  | Fe.LysM.2                      | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_Heme2.csv                   | 113  | Heme.2                        | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_HemeC32.csv                 | 113  | Heme.C3.2                     | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_HemeFVIII2.csv              | 113  | Heme.FViii.2                  | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2023identifying_HemeLysM2.csv                | 113  | Heme.LysM.2                   | clinical stage therapeutic, Fv   | [Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches](https://doi.org/10.1080/19420862.2023.2200540) | 2023 |
| jain2024assessment_Herapin_RT.csv                | 43   | Herapin Column Rel RT          | germline, Fv                    | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jain2024assessment_PSR.csv                        | 43   | PSR                           | germline, Fv                    | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| rosace2023automated_CICRT1_adalimumab.csv        | 14   | CIC RT (min) rep1             | Adalimumab, Fv                 | [Automated optimisation of solubility and conformational stability of antibodies and proteins](https://doi.org/10.1038/s41467-023-37668-6) | 2022 |
| rosace2023automated_CICRT1_golimumab.csv         | 5    | CIC RT (min) rep1             | Golimumab, Fv                 | [Automated optimisation of solubility and conformational stability of antibodies and proteins](https://doi.org/10.1038/s41467-023-37668-6) | 2022 |
| rosace2023automated_CICRT2_adalimumab.csv        | 14   | CIC RT (min) rep2             | Adalimumab, Fv                 | [Automated optimisation of solubility and conformational stability of antibodies and proteins](https://doi.org/10.1038/s41467-023-37668-6) | 2022 |
| rosace2023automated_CICRT2_golimumab.csv         | 5    | CIC RT (min) rep2             | Golimumab, Fv                 | [Automated optimisation of solubility and conformational stability of antibodies and proteins](https://doi.org/10.1038/s41467-023-37668-6) | 2022 |
| shanehsazzadeh2023unlocking_elisa_ec50.csv       | 13   | cELISA EC50 (pM)              | Trastuzumab, Fv               | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 |
| shanehsazzadeh2023unlocking_polyspecificity.csv  | 13   | Polyspecificity - Anti-DNA (AU) | Trastuzumab, Fv               | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 |
| shanker2024unsupervised_APC-MFI_Elotuzumab-Ixekuzimab.csv | 6 | APC-MFI                      | Elotuzumab, Ixekuzimab, Fv    | [Unsupervised evolution of protein and antibody complexes with a structure-informed language model](https://doi.org/10.1126/science.adk8946) | 2024 |
| shanker2024unsupervised_APC-MFI_Ly1404.csv        | 18   | APC-MFI                       | Ly1404, Fv                   | [Unsupervised evolution of protein and antibody complexes with a structure-informed language model](https://doi.org/10.1126/science.adk8946) | 2024 |
| shanker2024unsupervised_APC-MFI_SA58.csv          | 15   | ACP-MFI                       | SA58                         | [Unsupervised evolution of protein and antibody complexes with a structure-informed language model](https://doi.org/10.1126/science.adk8946) | 2024 |


# Additional data not included

`Ginkgo Datapoints developability assays` - https://datapoints.ginkgo.bio/what-we-do/antibody-developability



